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Diabetes is a metabolic disorder aﬀecting about 220 million people worldwide. One of the most critical complications of diabetes
is post-prandial hyper-glycemia (PPHG). Glucosidase inhibitor and α-amylase inhibitors are class of compounds that help in
managing PPHG. Low-cost herbal treatment is recommended due to their lesser side eﬀect for treatment of diabetes. Two plants
with signiﬁcant traditional therapeutic potential, namely, Gnidia glauca and Dioscorea bulbifera,w e r et e s t e df o rt h e i re ﬃciency
to inhibit α-amylase and α-glucosidase. Stem, leaf, and ﬂower of G. glauca a n db u l bo fD. bulbifera were sequentially extracted
with petroleum ether, ethyl acetate, and methanol as well as separately with 70% ethanol. Petroleum ether extract of ﬂower of G.
glauca was found to inhibit α-amylase signiﬁcantly (78.56%). Extracts were further tested against crude murine pancreatic, small
intestinal, and liver glucosidase enzyme which revealed excellent inhibitory properties. α-glucosidase inhibition provided a strong
in vitro evidence for conﬁrmation of both G. glauca and D. bulbifera as excellent antidiabetic remedy. This is the ﬁrst report of its
kind that provides a strong biochemical basis for management of type II diabetes using G. glauca and D. bulbifera. These results
provide intense rationale for further in vivo and clinical study.
1.Introduction
Diabetesmellitusisamultifactorialdisease.Itisanendocrine
and metabolic disorder characterized by chronic hypergly-
cemia [1]. Multiple biochemical impairments associate with
micro- and macrovascular complications which is a major
cause of morbidity and death in Diabetes mellitus [2, 3].
With the numbers of people aﬀected by diabetes multiplying
worldwide, the disease is taking an ever-increasing propor-
tionofnationalandinternationalhealthcarestrategies[4].It
is projected to become one of the world’s main disablers and
killers within the next 25 years [5–7]. The aﬀected most are
Asia and Africa, where DM rates are expected to rise by two-
to threefolds by 2030 [8]. The modern medicines available
for management of diabetes exert serious side eﬀects such
as hepatotoxicity, abdominal pain, ﬂatulence, diarrhea, and
hypoglycemia [9, 10]. Drug resistance to these medicines
is also reported after prolonged treatment. Therefore, apart
from currently available therapeutic options, many herbal
medicines have been recommended for treatment of dia-
betes [11]. Traditional herbal medicines have been used
throughout the world for a range of diabetes [12]. The α-
glucosidase inhibition signiﬁcantly decreases post-prandial
hyperglycemia (PPHG) in the treatment of type II diabetic
(T2DM)patients [13]. Thus, discovery of a suitable inhibitor
of glycosidase with minimum side eﬀects poses a challenge
in the search for a potent therapeutic agent. The search for
improved and safe natural antidiabetic agents is underway,
and the World Health Organization has also recommended
the development of herbal medicines in this concern [11,
14]. In view of this background, we selected two important2 Evidence-Based Complementary and Alternative Medicine
medicinal plants, Gnidia glauca and Dioscorea bulbifera for
the same.
G. glauca (Family-Thymelaeaceae) is used as traditional
phytomedicine for treating sore throat, abdominal pain,
wounds, burns, and snake bites [15]. Leaves have been ap-
plied to treat the contusions, swellings, back ache, and joint
aches [16]. It is considered as a powerful vesicant. It also has
agrochemical applications as a molluscicide, insecticide, pis-
cicide, and even larvicidal agents [17–19]. It has been shown
that several Gnidia species possess remarkable antineoplastic
activity [20]. It is used as an antiviral agent against rabies in
Ethiopia [21]. Its antidiabetic properties are not known.
D. bulbifera (Family-Dioscoreaceae) possess profound
therapeutic potential. It is found throughout the warmer
parts of India called as yam or air potato. It is widely used
in traditional Indian and Chinese medicine in the treatment
of sore throat, gastric cancer and carcinoma of rectum, and
goiter[22,23].Thevariousextractsofbulbsoftheplanthave
beenreportedtobeantihyperlipidemic [24],antitumor[25],
antioxidant [26], anorexiant [27], analgesic and anti-inﬂam-
matory [28], plasmid curing [29]a n da n t i h y p e r g l y c e m i c
[30].
It is important to note that there are no reports about
the antidiabetic activity of G. glauca till date. Similarly, no
research has been carried out to identify the targets that
can conﬁrm and support the antidiabetic potential of D.
bulbifera.Hence,wehaveinvestigatedinhibitoryeﬀectofvar-
ious extracts on commercially available porcine pancreatic
α-amylase and glucosidases from pancreas, liver, and small
intestine of Swiss mice. Furthermore, the inhibitory activity
was conﬁrmed against commercially available α-glucosidase
from Bacillus stearothermophilus. HPLC ﬁngerprints of the
extracts were developed for 55min and compared with the
standards like gallic acid, quercetin, and diosgenin.
2. Methods
2.1. Chemicals. α-glucosidase and 4-nitrophenyl α-D-gluco-
pyranoside were obtained from Sigma Aldrich, USA DNSA
(dinitrosalicylic acid) was obtained from SRL Pvt. Ltd.
(Mumbai, India). Petroleum ether, ethyl acetate, methanol,
ethanol, dipotassium hydrogen phosphate (K2HPO4), potas-
sium dihydrogen phosphate (KH2PO4), methanol, sodium
potassium tartarate, sodium hydroxide (NaOH), were po-
tassium from Qualigens, Mumbai, India. Porcine pancreatic
α-amylase and sodium chloride (NaCl) was obtained from
HiMedia Laboratories Mumbai, India. Acarbose was ob-
tained from Bayer Pharmaceuticals Pvt. Ltd. (Mumbai,
India). All the chemicals and reagents procured were of A.R.
grade.
2.2. Plant Material. Fresh, leaves, stems, and ﬂowers of G.
glauca and bulbs of D. bulbifera were collected in the month
of January from the Western Ghats, Maharashtra, India.
Plant materials were identiﬁed and authenticated by botanist
from National Research Institute of Ayurvedic Sciences,
Central Council for Research in Ayurveda and Siddha, Gov-
ernment of Ayush, Ministry of Health and Family Welfare,
Department Of India New Delhi, Nehru Garden, Kothrud
Pune, 411038. The specimen voucher number provided for
the G. glauca was 327 and D. bulbifera was 860.
2.3. Preparation of Plant Extracts. Leaves, stems, and ﬂowers
of G. glauca were shade dried at room temperature. Bulbs
of D. bulbifera were chopped into pieces and shade dried.
Dried plant materials were subjected to size reduction to a
coarse powder by using dry grinder. 100g of each of the
powder was packed into Soxhlet apparatus and extracted
successivelywithpetroleumether,ethylacetateandmethanol
at 80◦C (yield 2, 8, and 8%, resp.,). 100g of each powdered
plant material was also subjected to a cold extraction with
70% ethanol in distilled water. Petroleum ether, ethyl acetate
and methanol extracts were evaporated to dryness under
reduced pressure at 4◦C in rotary evaporator while ethanolic
extract was subjected to lyophilization and were stored in
air-tight containers in refrigerator at 4◦C. 20mg dry weight
of each crude extract was further reconstituted in 2mL of
10% dimethyl sulfoxide (DMSO) in distilled water and 1:20
dilution of all these extracts were used for α-amylase and the
glucosidase inhibition assays.
2.4.α-AmylaseInhibitionAssay. Amylaseactivitywasassayed
using a modiﬁed Bernfeld method (1955) using starch as
substrate. 50μgmL −1 (O.D. 0.4 at 280nm) of porcine pan-
creatic α-amylase was incubated with 1mgmL−1 samples at
37◦Cf o r1 0m i n[ 31]. One percent starch was used as sub-
strate. α-amylase without any extract was used as control.
ReducingsugarwasestimatedusingDNSAassayatA540nm
and the enzyme units were expressed as micro-molar per
minute [32]. One unit of enzyme was deﬁned as the amount
of enzyme required to liberate 1μM of maltose under assay
conditions. The ﬁnal inhibition shown by diﬀerent samples
were compared with the standard inhibitor, acarbose [33].
The inhibitory activity was calculated by using the formula
% Inhibition =
(A540Control −A540Test)
A540Control
×100. (1)
2.5. Glucosidase Inhibition Assay with Murine Pancreatic,
Liver, and Small Intestinal Extracts. 10-week-old Swiss male
mice weighing 20gm were procured from National Toxicol-
ogy Centre, Pune. Entire procedure was carried out with
guidelines of Institutional Animal Ethical Committee. The
mouse was starved for 12h. Pancreas, liver, and small intes-
tine tissues were excised and homogenized with 10mM ice
coldphosphatebuﬀercontaining6mMNaCl(1:10dilution;
w/v) and appropriate amount of protease inhibitors. Tissue
homogenates were centrifuged for 10min at 10,000r.p.m.
and the supernatant was taken as a source of enzyme that
wasdilutedsoastogetanabsorbanceof0.4(at280nm)[34].
Enzyme inhibition assay was carried out as described above.
Percentageinhibitionofthesamplesagainstpancreatic,small
intestinal, and liver glucosidases was calculated [35].
2.6. α-Glucosidase Inhibition Assay. Glucosidase inhibition
assay of extracts of the leaves, stem, and ﬂower of G. glaucaEvidence-Based Complementary and Alternative Medicine 3
and bulbs of D. bulbifera was carried out as per Sanap et al.,
2010 [36]. In brief, 0.1unit/mL of α-glucosidase was mixed
with each of the samples and incubated for 1h at 37◦C.
Enzyme action for α-glucosidase was initiated by addition
of 2mM p-nitrophenyl-α-D-glucopyranoside in 100mM
phosphate buﬀer of pH 6.8 and stopped by adding 2mL
of 0.1MNa2CO3 after an incubation of 10min at 37◦C. α-
Glucosidase activity was determined by measuring absorb-
ance of the p-nitrophenol released from pNPG at 420nm
using Shimadzu Spectrophotometer UV-1601. One unit of
glucosidase activity is deﬁned as the amount of enzyme that
hydrolyzed 1μMo fp-nitrophenyl pyranoside per minute
under assay condition.
2.7. Development of HPLC Fingerprints. AL C - 6 A DS h i -
madzu liquid chromatograph system with automated gra-
dient controller, SPD-M20A Photo Diode Array UV-Vis
detector and Phenomenex Luna 5μ C-18 column (250 ×
4.6mm ID) was used. 1mL of HPLC grade methanol was
added to 1mg of sample and sonicated for 10min followed
by centrifugation at 3000rpm for 15min. The volume was
made upto 10mL with methanol and the solution was ﬁl-
tered through 0.22μm ﬁlter (Millipore). 20μL of sample was
injected for development of the chromatogram for 55min.
A binary gradient with mobile phase containing: (solvent
A) water-acetic acid (0.5%v/v) and (solvent B) acetonitrile:
water-acetic acid (99.5–0.5) = 80:20 (v/v).The ﬂow-rate was
maintained constant at 1mL/min and the solvent gradient
elution program was as follows: 0–10min, 90% A, 10% B;
10–20min, 90–80% A, 10–20% B; 20–30min, 80–60% A,
20–40% B; 30–40min, 60–40% A, 40–60% B; 40–45min,
40–30%A,60–70%B;and45–50min,30–90%A,70–10%B.
2.8. Statistical Analysis. A l lv a l u e sw e r ee x p r e s s e da sm e a n±
standard error of mean (S.E.M.), n = 3, and analyzed for
ANOVA and two tailed Student’s t-test (P<0.05) [37].
3. Results
3.1. Porcine Pancreatic α-Amylase Inhibitory Activity of Plant
Extracts. In vitro α-amylase inhibitory studies demonstrat-
ed that the extracts of both G. glauca as well as D. bulbifera
had inhibitory activity. Porcine pancreatic α-amylase with
0.29Umin−1 was taken as 100% enzymatic activity. Signiﬁ-
cant inhibition was exhibited by petroleum ether extract of
leaf (IC50 = 34.88μg/mL), and ﬂower (IC50 = 31.82μg/mL)
while D. bulbifera bulb showed 61.65% (Figure 1). Ethanolic
extract of ﬂower exhibited 77.93% inhibition with pure
porcine α-amylase. Even ethyl acetate (IC50 = 33.84μg/mL),
and methanol (IC50=33.92μg/mL) extract of ﬂower showed
very high inhibition. A signiﬁcant inhibition of 73.39% was
exhibited by ethyl acetate extract of D. bulbifera b u l b sa sw e ll .
Both ethyl acetate, and methanol extracts of leaf showed
a considerable inhibition of 62.91 and 62.75% against α-
amylase. Methanol and 70% ethanol extracts of D. bulbifera
showed considerable inhibition as well. Thus, a signiﬁcant
inhibition was observed with extracts of ﬂower of G. glauca
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Figure 1: The percent α-amylase inhibition by plant extracts.
Acarbose is taken as standard inhibitor. The data is indicated as the
mean ± SEM; [n = 3].
and bulbs of D. bulbifera bulbs; whereas the extracts of stem
showed inhibition lower than both leaf and stem.
3.2. Murine Pancreatic Glucosidases Inhibitory Activity of
Plant Extracts. Murine pancreatic enzyme activity exhibit-
ing 0.24Umin−1 was taken as 100% enzymatic activity.
PetroleumetherextractofD.bulbiferabulbexhibited22.23%
inhibition against murine pancreatic glucosidase, whereas G.
glauca showed comparatively moderate inhibition of 16.18,
15.92, and 16.37% with stem, leaf, and ﬂower, respectively.
In case of ethyl acetate as well D. bulbifera bulb was found
to be potent inhibitor showing an inhibition of 23.59%. G.
glaucashowed comparable inhibition with each of stem, leaf,
and ﬂower. Similar trend was observed in case of methanol
and 70% ethanol extract where D. bulbifera showed 26%
and 18.13%, respectively. Methanol extract of D. bulbifera
showedsigniﬁcantdiﬀerencewithP<0.05ascomparedwith
other extracts (Table 1).
3.3. Murine Small Intestinal Glucosidases Inhibitory Activity
of Plant Extracts. Murine small intestinal glucosidase with
0.12Umin−1 was taken as 100% enzymatic activity. Petrole-
um ether extract of D. bulbifera bulb (IC50 = 33.62μg/mL)
showed a maximum inhibition of 74.36% that was found
to be more potent as compared to acarbose (IC50 =
48.79μg/mL). Petroleum ether extract of G. glauca ﬂower
showed a maximum inhibition of 57.84%. Ethyl acetate
(IC50 = 43.22μg/mL), methanol (IC50 = 43.47μg/mL), and
70% ethanol extract (IC50 = 40.4μg/mL) of G. glauca ﬂower
showed inhibition comparable to acarbose (Table 2). Ethyl
acetate extract of D. bulbifera bulb was found to be having
an inhibition percentage of 51.41 which was signiﬁcant as
compared to both methanol and 70% ethanol extracts.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Percent murine pancreatic glucosidase inhibition by plant extracts.
Acarbose [40.89 ±1.03] % Glucosidase inhibitory activity
Petroleum ether Ethyl acetate Methanol Ethanol [70%]
G. glauca
Stem 16.81 ±0.25 19.32 ±1.64 16.37 ±1.35 13.12 ±1.96
Leaf 15.92 ±1.91 9 .76 ±1.94 18.76 ±1.88 14.3 ±1.03
Flower 16.37 ±2.61 3 .71 ±2.11 18.87 ±0.89 16.07 ±2.48
D. bulbifera
Bulb 22.23 ±2.71 23.59 ±0.71 26.1 ±0.87 18.13 ±0.15
The data is indicated as the mean ± SEM; [n = 3].
Table 2: Percent murine small intestinal glucosidase inhibition by plant extracts.
Acarbose [51.23 ±0.89] % Glucosidase inhibitory activity
Petroleum ether Ethyl acetate Methanol Ethanol [70%]
G. glauca
Stem 57.18 ±3.75 55.55 ±2.43 52.28 ±3.59 47.38 ±2.84
Leaf 52.61 ±1.27 50 ±3.53 49.34 ±2.01 42.81 ±3.28
Flower 57.84 ±2.92 56.84 ±1.44 57.51 ±1.81 51.23 ±0.81
D. bulbifera
Bulb 74.36 ±2.72 51.41 ±0.75 50.24 ±0.83 43.54 ±0.18
The data is indicated as the mean ± SEM; [n = 3].
3.4. Murine Liver Glucosidases Inhibitory Activity of Plant
Extracts. Murine liver glucosidase with 0.75Umin−1 was
taken as 100% enzymatic activity. D. bulbifera bulb showed
a maximum inhibition of 73.36% amongst the petroleum
ether extracts while ethyl acetate extract of stem of G. glauca
showed a potent inhibition of 80%. Methanol extract of G.
glauca leaf (IC50 = 32.61μg/mL) showed excellent inhibition
that was found to be most signiﬁcant with P<0.05 as com-
pared with other plant extracts as well as acarbose (Table 3).
Amongst the 70% ethanol extracts, D. bulbifera exhibited a
maximum inhibition up to 53.3%.
3.5. α-Glucosidase Inhibitory Activity of Plant Extracts.
0.1Umin−1 of α-glucosidase was taken as 100% enzymatic
activity. Petroleum ether extract of D. bulbifera showed
strong inhibitory potential with a percentage inhibition of
92.87% as compared to acarbose. Stem, leaf, and ﬂower
of G. glauca showed moderate inhibition of 43.54, 21.77
and 51.23%, respectively (Figure 2). Ethyl acetate extract of
D. bulbifera bulb was found to be the strongest inhibitor
showing an inhibition as high as 99.6%. Similarly, methanol
and 70% ethanol extracts of D. bulbifera bulbs exhibited an
inhibition of 98.81 and 79.27% which were most signiﬁcant
as compared to others.
3.6. HPLC Fingerprinting. In this study an HPLC method
was developed to achieve shorter runtime (55min) with
gradual increase of organic phase (acetonitrile). Gallic acid,
quercetin, and diosgenin were used as standards. HPLC
ﬁngerprinting showed the high content of diosgenin in the
methanol extract of D. bulbifera bulb. A binary gradient
system consisting of water-acetonitrile-acetic acid as mobile
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Figure 2: The percent α-glucosidase inhibition by plant extracts.
Acarbose is taken as standard inhibitor. The data is indicated as the
mean ± SEM; [n = 3].
phase was able to separate the compounds in the extracts
(Figure 3). The developed HPLC method was applied for
detect of the marker compounds and to assess the number
of unidentiﬁed peaks that indicated the variability in the
phytochemical proﬁle of the plant materials. The overlay
HPLCﬁngerprints(Seeﬁgures21-24issupplementarymate-
rial available online at doi: 10.1155/2012/929051) were used
to assess the sample similarity against a generated reference
chromatogram. In case of D. bulbifera the variability was
observed mostly in case of ethyl acetate and methanolEvidence-Based Complementary and Alternative Medicine 5
Table 3: Percent murine liver glucosidase inhibition by plant extracts.
Acarbose [37.33 ±0.69] % Glucosidase inhibitory activity
Petroleum ether Ethyl acetate Methanol Ethanol [70%]
G. glauca
Stem 70 ±3.28 80 ±0.56 70 ±0.59 66.67 ±1.09
Leaf 56.66 ±2.71 80 ±0.71 76.66 ±0.87 73.33 ±0.15
Flower 99 ±1.12 93.33 ±1.99 3 .34 ±1.59 0 ±1.81
D. bulbifera
Bulb 73.3 ±2.73 40 ±0.74 43.3 ±0.81 53.3 ±0.17
The data is indicated as the mean ± SEM; [n = 3].
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Figure 3: A representative HPLC ﬁngerprint of plant extract (a) D. bulbifera methanol extract and (b) HPLC chromatogram of a standard
solution containing three marker compounds.
extracts. In case of G. glauca leaf the maximum diversity in
the phytochemistry was characterized by twenty ﬁve peaks
with diﬀerent Rt values. Similarly, twenty-two peaks in the
methanolic extract of G. glauca ﬂower also notably indicated
the presence of relatively high amount of phytochemicals of
polar nature. Signiﬁcant number of peaks in the ethyl acetate
extract showed the dominance of the probable ﬂavonoids or
terpenoidcompoundsinbothD. bulbifera andG.glauca.The
chromatogram also showed several other unidentiﬁed peaks
as shown in Table 4.
4. Discussion
Herbal extracts and herbal formulations, used in the
Ayurvedic literarture, have recently been reviewed and have
gained importance for the control of T2DM. They are being
used directly or indirectly for the preparation of many
modern drugs [12]. Although G. glauca and D. bulbifera
have been used for thousands of years as ingredients in
Ayurvedic and Chinese traditional medicine, they have not
gained much importance as medicines and one of the factors
being lack of speciﬁc standards being prescribed for herbal
medicines and supportive animal/clinical trials [38]. In the
present study, we investigated both the plants for their possi-
blesigniﬁcanceincontrolofT2DMbyglucosidaseinhibitory
activity. Plants have wide array of phytochemicals ranging
from both nonpolar to polar. Thus, plant materials were
sequentially extracted to ensure complete extraction of all
non-polar as well as polar components and thereby inclusion
ofallcomponentsinthescreeningstudy.Plantsareknownto
producealargevarietyofglucosidaseinhibitorsthatprovides
protection against insects and microbial pathogens [39,
40]. Therefore, plant extracts were analyzed for α-amylase
inhibitory activity. Pancreatic and intestinal glucosidases
are the key enzymes of dietary carbohydrate digestion and
inhibitors of these enzymes may be eﬀective in retarding
glucose absorption to suppress PPHG. In T2DM, excessive
hepatic glycogenolysis and gluconeogenesis is associated
with decreased utilization of glucose by tissues being the
fundamental mechanism underlying hyperglycemia [41].
The liver glucosidase inhibitors inhibit α-1,6-glucosidase
of glycogen-debranching enzymes in the liver and reduce
the glycogenolytic rate which increases the accumulation
of glycogen stores in the liver [42, 43]. Inhibition of these
enzyme systems decreases the current blood glucose levels
in diabetic patient (as a short-term eﬀect) and shows a
small reduction in hemoglobin A1c level (as a long-term
eﬀect).6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Representative dose response curves for plant extracts. (a) Petroleum ether extracts against porcine pancreatic α-amylase; (b)
ethyl acetate extracts against murine pancreatic glucosidase; (c) petroleum ether extracts against murine small intestinal glucosidase; (d)
petroleum ether extracts against murine liver glucosidase: (e) ethyl acetate extracts against α-glucosidase.8 Evidence-Based Complementary and Alternative Medicine
Our investigation provides the ﬁrst evidence of antidia-
b e t i cp r o p e r t yo fe x t r a c t so fG. glauca. On the other hand,
D. bulbifera is a comparatively well-studied plant system due
to its anticancer and antioxidant activity [22, 26]. It is widely
used in Asia as a rich and sustainable source of carbohydrate.
Traditionally, it has gained importance for its antiobese and
antihyperglycemic properties. However, there is no scientiﬁc
evidence for this fact and hereby our investigation is a
novel approach to identify the targets involved for lowering
the glycemic index and the control of post-prandial hyper-
glycemia. In our study, for the ﬁrst time a detailed biochemi-
cal basis of the antidiabetic activity is presented that involves
theinhibitionofnotonlythepureα-amylaseandglucosidase
aswellasthecrudemurineenzymeswhicharethekeyplayers
of the T2DM. Recently, a preliminary study has shown the
antihyperglycemic and antihyperlipidemic activity of D. bul-
bifera on Wistar rats [30]. Hence, there is a need to ﬁnd out
the biochemical basis of lowering of glycemic index in vitro.
Plantextractsareknowntobepotentα-amlaseinhibitors
due to their rich phenolic content that bind to the reactive
sites of enzymes, thus altering its catalytic activity [44]. It
has been suggested that the mechanism of inhibition of α-
amylase may occur through the direct blockage of the active
centre at several subsites of the enzyme as also suggested for
other inhibitors [45]. A signiﬁcant variability in the levels
of enzyme inhibition between the parts of the same plant
evident in the dose response curves (Figure 4) suggests the
phytochemical diversity among the parts resulting in varia-
tion in the antidiabetic property. Dose response curves for
all extracts against, α-amylase, murine pancreatic, intestinal,
liver glucosidases, and α-glucosidase are given in the sup-
plementary information. Our study revealed that petroleum
ether extract of G. glauca ﬂower (78.56%) and methanolic
extract of D. bulbifera bulbs (73.54%) were potent α-
amylase inhibitors. Various herbal extracts like Bougainvillea
spectabilis and Trigonella foenum-graecum seeds are known
as α-amylase inhibitors showing 29.43% and 59%, respec-
tively [35, 46]. Thus, G. glauca and D. bulbifera exhibited
comparatively more eﬃcient α-amylase inhibition.
The inhibition observed for extracts of D. bulbifera
bulbs against murine pancreatic glucosidase was found to
be comparable as earlier reports on other Indian medicinal
plants such as Linum usitatissimum methanolic extract [35].
Similarly, leaf extract of Murraya koenigii and Azadirachta
indica are reported to show 43.71% and 41.7% inhibition
against murine small intestinal glucosidase, respectively. We
found that, the methanolic extract of both G. glauca and D.
bulbifera were found to be superior showing an inhibition
at a range of 50–58%. Petroleum ether of D. bulbifera
bulbs exhibited an inhibition of 73.3% against murine liver
glucosidase which was more potent as compared to the
maximum inhibition percent of Bougainvillea spectabilis,
Ocimum tenuiﬂorum,a n dSyzygium cumini as reported
earlier. However, extracts of G. glauca were found to have
superior inhibitory property, particularly petroleum ether
extract of ﬂower that exhibited an inhibition in the range of
90–99% while methanol extract of leaf showed highest inhi-
bition (IC50 = 25.2μg/mL) against murine liver glucosidase.
Ethanolic extract of Andrographis paniculata was reported to
inhibit α-glucosidase up to 89% only at signiﬁcantly high
concentration of 62.5mg/mL [47]. However, methanolic
extract of G. glauca leaf and ethyl acetate extract of D. bulb-
ifera showed an inhibition of 99.19 and 99.6%, respectively,
atconsiderablylowconcentrations(66.65μg/mL).Moreover,
the strong inhibition by methanol extract of ﬂower (IC50 =
53.74μg/mL) against the pure α-glucosidase from Bacillus
stearothermophilus conﬁrmed the antidiabetic property of G.
glauca as well as its variability on the basis of the parts of
plant selected. HPLC ﬁngerprint indicated the presence of
diosgenin in the methanolic extracts of D. bulbifera bulbs.
The maximum number of peaks in the ethyl acetate fractions
might be due to the rich ﬂavonoids and terpenoid content in
the plant materials.
We, for the ﬁrst time, have explored G. glauca and D.
bulbifera as potential glycosidase inhibitors. Presently, we
have identiﬁed the targets of the extracts being the α-amylase
and α-glucosidase as well as pancreatic, intestinal, and liver
enzymes that are principally responsible for hyperglycemia
in diabetes. They can further be studied and used as dietary
supplement for controlling PPHG in type II diabetes.
5. Conclusions
G. glauca and D. bulbifera show signiﬁcant inhibition with
porcine pancreatic amylase and crude murine glucosidase as
well as pure α-glucosidase. This may have beneﬁcial eﬀects
in managing type II diabetes mellitus and could be used as
eﬀective herbal formulation in combinational therapy which
can be taken up in further studies.
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